Guangshengtang (300436.SZ): GST-HG131, an innovative drug for hepatitis B treatment, obtained a phase II clinical study summary report

Zhitongcaijing · 05/14/2025 13:17

Zhitong Finance App News, Guangshengtang (300436.SZ) announced that the company's innovative hepatitis B treatment drug GST-HG131 has completed phase II clinical trials for chronic hepatitis B, and recently obtained a research summary report on the phase II clinical trial. Research results showed that GST-HG131 tablets had a clear inhibitory effect on the hepatitis B surface antigen HBsAg in patients with chronic hepatitis B, and were safe.